ATE254128T1 - Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen - Google Patents

Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen

Info

Publication number
ATE254128T1
ATE254128T1 AT99302969T AT99302969T ATE254128T1 AT E254128 T1 ATE254128 T1 AT E254128T1 AT 99302969 T AT99302969 T AT 99302969T AT 99302969 T AT99302969 T AT 99302969T AT E254128 T1 ATE254128 T1 AT E254128T1
Authority
AT
Austria
Prior art keywords
spla2
treating
related diseases
tricyclic compounds
substituted tricyclic
Prior art date
Application number
AT99302969T
Other languages
English (en)
Inventor
Nicholas James Bach
Jolie Anne Bastian
Douglas Wade Beight
Michael Dean Kinnick
Michael John Martinelli
Edward David Mihelich
John Michael Morin Jr
Daniel Jon Sall
Jason Scott Sawyer
Edward C R Smith
Tulio Suarez
Qiuping Wang
Thomas Michael Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE254128T1 publication Critical patent/ATE254128T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
AT99302969T 1998-04-17 1999-04-16 Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen ATE254128T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6216598A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
ATE254128T1 true ATE254128T1 (de) 2003-11-15

Family

ID=22040624

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01203116T ATE259818T1 (de) 1998-04-17 1999-04-16 Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
AT99302969T ATE254128T1 (de) 1998-04-17 1999-04-16 Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01203116T ATE259818T1 (de) 1998-04-17 1999-04-16 Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen

Country Status (27)

Country Link
EP (2) EP1156050B1 (de)
JP (1) JP4435325B2 (de)
KR (1) KR19990083234A (de)
CN (1) CN1235968A (de)
AR (1) AR018185A1 (de)
AT (2) ATE259818T1 (de)
AU (1) AU757454B2 (de)
BR (1) BR9901275A (de)
CA (1) CA2269256A1 (de)
CO (1) CO5080728A1 (de)
CZ (1) CZ137199A3 (de)
DE (2) DE69914951T2 (de)
EA (1) EA003129B1 (de)
ES (2) ES2210979T3 (de)
HU (1) HUP9901219A1 (de)
ID (1) ID23219A (de)
IL (1) IL129484A0 (de)
NO (1) NO991823L (de)
NZ (1) NZ335252A (de)
PE (1) PE20000472A1 (de)
PL (1) PL332564A1 (de)
SG (1) SG106035A1 (de)
SV (1) SV1999000052A (de)
TR (1) TR199900842A2 (de)
TW (1) TW555760B (de)
YU (1) YU19099A (de)
ZA (1) ZA992773B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513555A (ja) * 1997-08-28 2001-09-04 イーライ・リリー・アンド・カンパニー 非リウマチ様関節炎の処置方法
WO2001074817A1 (en) * 2000-03-30 2001-10-11 Yamanouchi Pharmaceutical Co., Ltd. Hydrazide derivatives
EP1303262A2 (de) * 2000-07-14 2003-04-23 Eli Lilly And Company Verwendung eines spla2-hemmers zur behandlung von sepsis
EP1349836B1 (de) * 2000-12-18 2006-06-14 Eli Lilly And Company Tetracyclische derivate als spla2 inhibitoren
ATE353876T1 (de) * 2001-03-28 2007-03-15 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
JP2005527464A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
JP2005527466A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体
US6992100B2 (en) 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
EP1807427A2 (de) 2004-11-01 2007-07-18 Wyeth Substituierte indolizine und derivate als zns-wirkstoffe
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
MY165623A (en) * 2011-04-14 2018-04-18 Idorsia Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
JP6114815B2 (ja) 2012-03-16 2017-04-12 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 肝臓ｘレセプターモジュレーター
EP2825541B1 (de) 2012-03-16 2016-06-22 Vitae Pharmaceuticals, Inc. Leber-x-rezeptormodulatoren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
ES2208685T3 (es) * 1994-07-21 2004-06-16 Eli Lilly And Company Inhibidores de indolizina spla2.
WO1997021664A1 (en) * 1995-12-13 1997-06-19 Eli Lilly And Company NAPHTHYL ACETAMIDES AS sPLA2 INHIBITORS
CN1233176A (zh) * 1996-10-30 1999-10-27 伊莱利利公司 取代的三环化合物
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Also Published As

Publication number Publication date
SV1999000052A (es) 2000-03-14
EP1156050A3 (de) 2001-11-28
ATE259818T1 (de) 2004-03-15
NZ335252A (en) 2000-11-24
DE69912670D1 (de) 2003-12-18
ES2213668T3 (es) 2004-09-01
EP1156050B1 (de) 2004-02-18
HU9901219D0 (en) 1999-06-28
JP4435325B2 (ja) 2010-03-17
AU757454B2 (en) 2003-02-20
SG106035A1 (en) 2004-09-30
CN1235968A (zh) 1999-11-24
PE20000472A1 (es) 2000-06-02
EA199900304A2 (ru) 1999-10-28
DE69914951T2 (de) 2004-12-23
PL332564A1 (en) 1999-10-25
AU2381899A (en) 1999-10-28
AR018185A1 (es) 2001-10-31
KR19990083234A (ko) 1999-11-25
TR199900842A2 (xx) 2000-09-21
EP1156050A2 (de) 2001-11-21
EP0950661B1 (de) 2003-11-12
ID23219A (id) 2000-03-30
ES2210979T3 (es) 2004-07-01
ZA992773B (en) 2002-07-16
IL129484A0 (en) 2000-02-29
CA2269256A1 (en) 1999-10-17
EA199900304A3 (ru) 2000-04-24
CO5080728A1 (es) 2001-09-25
DE69914951D1 (de) 2004-03-25
NO991823D0 (no) 1999-04-16
JPH11322745A (ja) 1999-11-24
TW555760B (en) 2003-10-01
HUP9901219A1 (hu) 2000-08-28
YU19099A (sh) 2001-09-28
DE69912670T2 (de) 2004-08-12
EA003129B1 (ru) 2003-02-27
EP0950661A1 (de) 1999-10-20
CZ137199A3 (cs) 1999-11-17
BR9901275A (pt) 2000-05-02
NO991823L (no) 1999-10-18

Similar Documents

Publication Publication Date Title
ATE255888T1 (de) Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE251903T1 (de) Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
DE69920019D1 (de) Behandlung von mineralfüllstoffen mit phosphaten, diese füllstoffe und deren verwendung
ATE236529T1 (de) Antiparasitäre zusammensetzung zur behandlung und zum schutz von haustieren
ATE267015T1 (de) Verbindungen und verfahren zur behandlung von krebs
DE69812603D1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69722681D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69831222D1 (de) Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
ATE200863T1 (de) Indolinonverbindungen zur behandlung von krankheiten
ATE230617T1 (de) Verfahren und methode zur behandlung von abfällen
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
DE60013859D1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ATE259818T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
ATE227127T1 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
EP0758894A4 (de) Verwendung von alpha-1c spezifischen verbindungen zur behandlung der benignen prostatahyperplasie
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
EP1117395A4 (de) Verbindungen zur behandlung von östrogenabhängigen erkrankungen und deren herstellungs und verwendungsmethoden
DE69835419D1 (de) Verfahren zur Behandlung von organischem Abwasser
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE258062T1 (de) Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren
ATE222910T1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties